TLDR New compounds may help treat prostate cancer by reducing cell growth.
The study found that dehydroepiandrosterone derivatives 2a-b, 3a-f, and 4a-f significantly reduced the proliferation of LNCaP cells, a type of prostate cancer cell, compared to testosterone treatment. Unlike finasteride, these derivatives decreased cell viability and inhibited the conversion of testosterone to dihydrotestosterone at high concentrations. This suggests that these derivatives have potential as therapeutic agents for treating metastatic prostate cancer.
3 citations
,
June 2018 in “Bioorganic & medicinal chemistry” Compounds 4, 4b, and 4c effectively inhibit an enzyme linked to testosterone conversion without significant toxicity.
14 citations
,
June 2011 in “Steroids” New compounds may help treat prostate issues without affecting androgen receptors.
70 citations
,
June 1993 in “Biochemistry” Finasteride slowly binds to 5-alpha-reductase, affecting enzyme stability and inhibitor potency.
June 2023 in “Clinica Chimica Acta” Finasteride and dutasteride effectively reduce DHT in hair, which may help evaluate their treatment success for hair loss.
65 citations
,
October 1999 in “Journal of The American Academy of Dermatology” Finasteride effectively reduces hair loss by decreasing androgen levels.
59 citations
,
September 1994 in “The Journal of Clinical Endocrinology and Metabolism” Finasteride reduces scalp DHT levels, potentially treating male pattern baldness.
